Trials Sponsors Conditions Drugs Pricing

Conditions

Cancer Chronic Pain Neuropathic Pain Opioid Use

Keywords

CancerPalliative careKetamineChronic pain

Outcome Measures

Primary Outcomes (2)

Describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication
neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation
Up to 3 months after inclusion
Describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of administration protocol
route, posology, duration, administration sequence, premedication
Up to 3 months after inclusion

Secondary Outcomes (6)

Evaluate in the context of cancer the antalgic efficacy
Up to 3 months after inclusion

Interventions

Ketamine use in CLCC sites (indication and administration protocol)Drug

Collection of information concerning Ketamine use by French CLCCs pain teams (first prescription): 1. Indications : analgesic treatment of cancer chronic pain, analgesic treatment for a post-cancer treatment chronic pain, help for withdrawal from opioid treatment prescribed for a chronic cancer pain 2. Administration protocol: route, posology, duration, administration sequence, premedication 3. Antalgic efficacy 4. Tolerance profile 5. Quality of life, anxiety and depression evaluations

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

This is a prospective, multicentre study, considered as " non-RIPH (Recherche n'Impliquant pas la Personne Humaine ". Indeed, the patient's participation in the study and the completion of the various questionnaires has no impact on patient's safety and is not likely to change his/her management. The treatment will be conducted according to the standard practices of each participating site (continuous or discontinuous protocol, dosage, rhythm of administration, monitoring, etc.). The questionnaires and scales used in this study are part of the recommended tools for monitoring this population.

You may qualify if:

Sponsors & Collaborators

Centre Leon Berard
Otherlead

Study Sites (12)

Institut Bergonié

Bordeaux, 33076, France

Centre François Baclesse

Caen, France

Centre Jean Perrin

Clermont-Ferrand, 63011, France

Centre Leon Berard

Lyon, 69008, France

Institut Paoli Calmettes

Marseille, 13273, France

Institut de Cancérologie de Montpellier

Montpellier, 34298, France

Institut Curie

Paris, 75005, France

MeSH Terms

Conditions

NeoplasmsChronic PainNeuralgia

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System Diseases

Study Officials

Gisèle CHVETZOFF, MD
Centre Leon Berard
PRINCIPAL INVESTIGATOR

Enrollment

81 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 1, 2020

First Posted

July 7, 2020

Study Start

February 2, 2021

Actual (reported)

Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (6)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (12)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (6)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (12)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations